While p53 is the most commonly mutated gene in human cancers, a large subset of tumors with wild-type p53 overexpress MDM2, an observation that has led to the development of therapeutics designed to block the MDM2-p53 interaction [68]. This evidence concerns the gene MDM2 and cancer.